CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...
Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with systemic lupus erythematosus who received ...
Immune cells that have been genetically engineered to kill cancerous cells, known as CAR T-cells, have transformed the treatment of blood cancers such as leukaemia, but have proved largely ineffective ...
Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...
As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...
CELLS develops off-the-shelf TALEN-edited CAR-T therapies. Its main in-house asset is lasme-cel for r/r B-ALL and eti-cel for r/r B-cell NHL. Early data show that lasme-cel reached impressive ORRs in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results